Top

Published in:

Open Access 01-12-2021 | Migraine | Research article

Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey

Authors: M. Koch, Z. Katsarava, C. Baufeld, K. Schuh, A. Gendolla, A. Straube, W. von Pannwitz, W. E. Hofmann, S. Ortler

Published in: The Journal of Headache and Pain | Issue 1/2021

Abstract

Background

Migraine is a primary headache disorder characterized by recurrent attacks that may have a significant impact on patients’ daily life. Treatment options must often be re-evaluated in light of efficacy, tolerability and compliance issues. Few data on commonly applied treatment algorithms and treatment failures have existed in Germany in 2017/2018. The PANORAMA survey was designed to explore and characterize the migraine healthcare landscape and to demonstrate the medical treatment need at that time in Germany.

Methods

Three different questionnaires were used to assess the profile of the 119 participating centers, characterize migraine patients at centers and evaluate qualitative aspects of the current migraine healthcare situation from a physician´s professional perspective. Data were analyzed as observed and summarized by descriptive statistics.

Results

The results demonstrate that once referred to a migraine specialist, the majority of patients continue to be treated at a specialist. At specialized centers, 41.6 % of migraine patients receive prophylactic treatment. 45.4 % of prophylactic treatments are initiated with a beta-blocker and 28.1 % with an anti-epileptic. Pivotal factors to initiate prophylactic treatment are migraine attack frequency and intensity (58.0 %). Treatment decisions are largely based on prior / concomitant diseases and physical constitution of the patient (52.1 %). Following an inadequate treatment, most patients either switch substance class or discontinue prophylactic treatment.

Conclusions

PANORAMA gives a comprehensive overview of the migraine healthcare landscape in Germany in 2017/2018, elucidates a lack of common treatment algorithms and reveals a high demand for defined therapy strategies and new prophylactic treatment going forwards.

Available only for authorised users

Steiner TJ, Stovner LJ, Vos T (2016) GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain 17(1):104. doi:https://doi.org/10.1186/s10194-016-0699-5CrossRefPubMedPubMedCentral

Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S (2018) Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19(1):82. doi:https://doi.org/10.1186/s10194-018-0907-6CrossRefPubMedPubMedCentral

Steiner TJ, Stovner LJ, Katsarava Z et al (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 15:31. doi:https://doi.org/10.1186/1129-2377-15-31CrossRefPubMedPubMedCentral

Gibbs TS, Fleischer AB, Feldman SR, Sam MC, O’Donovan CA (2003) Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache 43(4):330–335. doi:https://doi.org/10.1046/j.1526-4610.2003.03067.xCrossRefPubMed

Lipton RB, Stewart WF, Simon D (1998) Medical consultation for migraine: results from the American Migraine Study. Headache 38(2):87–96. doi:https://doi.org/10.1046/j.1526-4610.1998.3802087.xCrossRefPubMed

Giamberardino M, Affaitati G, Costantini R, Cipollone F, Martelletti P (2017) Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res 10:2751–2760. doi:https://doi.org/10.2147/JPR.S128143CrossRefPubMedPubMedCentral

Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm JMCP 20(1):22–33. doi:https://doi.org/10.18553/jmcp.2014.20.1.22CrossRefPubMed

Giamberardino MA, Martelletti P (2015) Emerging drugs for migraine treatment. Expert Opin Emerg Drugs 20(1):137–147. doi:https://doi.org/10.1517/14728214.2015.999040CrossRefPubMed

Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain 19(1):10. doi:https://doi.org/10.1186/s10194-018-0839-1CrossRefPubMedPubMedCentral

10.

Andrée C, Stovner LJ, Steiner TJ et al (2011) The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain 12(5):541–549. doi:https://doi.org/10.1007/s10194-011-0356-yCrossRefPubMedPubMedCentral

11.

de Vries T, Villalón CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. Published online March 12:107528. doi:https://doi.org/10.1016/j.pharmthera.2020.107528CrossRef

12.

Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E. Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis. Headache Published online April 30, 2020. doi:https://doi.org/10.1111/head.13828

13.

Tseng P-T, Yang C-P, Su K-P et al (2020) The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res Published online April 29:e12663. doi:https://doi.org/10.1111/jpi.12663

14.

Visser EJ, Drummond PD, Lee-Visser JLA. Reduction in Migraine and Headache Frequency and Intensity with Combined Antioxidant Prophylaxis (N-acetylcysteine, Vitamin E and Vitamin C: NEC): A Randomized Sham-Controlled Pilot Study. Pain Pract Off J World Inst Pain Published online April 19, 2020. doi:https://doi.org/10.1111/papr.12902

15.

Locher C, Kossowsky J, Koechlin H et al. Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis: A Systematic Review and Network Meta-analysis. JAMA Pediatr Published online February 10, 2020. doi:https://doi.org/10.1001/jamapediatrics.2019.5856

16.

Frederiksen SD, Bekker-Nielsen Dunbar M, Snoer AH, Deen M, Edvinsson L. Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis. Headache Published online April 15, 2020. doi:https://doi.org/10.1111/head.13802

17.

Deng H, Li G-G, Nie H et al (2020) Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol 20(1):57. doi:https://doi.org/10.1186/s12883-020-01633-3CrossRefPubMedPubMedCentral

18.

Goadsby PJ, Reuter U, Hallström Y et al (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377(22):2123–2132. doi:https://doi.org/10.1056/NEJMoa1705848CrossRefPubMed

19.

Müller B, Dresler T, Gaul C et al (2020) Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study. J Headache Pain 21(1):49. doi:https://doi.org/10.1186/s10194-020-01099-1CrossRefPubMedPubMedCentral

Title: Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey
Authors: M. Koch
Z. Katsarava
C. Baufeld
K. Schuh
A. Gendolla
A. Straube
W. von Pannwitz
W. E. Hofmann
S. Ortler
Publication date: 01-12-2021
Publisher: Springer Milan
Keywords: Migraine
Care
Headache
Published in: The Journal of Headache and Pain / Issue 1/2021
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-021-01316-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Medication overuse and drug addiction: a narrative review from addiction perspective

Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury

Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea

Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study

The relationship between headache-attributed disability and lost productivity: 1. A review of the literature

Interleukin-6 induces spatially dependent whole-body hypersensitivity in rats: implications for extracephalic hypersensitivity in migraine